SQ 29548 is a selective TXA2R antagonist. SQ 29548 blocks thromboxane-prostanoid receptor signaling to inhibit serotonin-induced vasoconstriction. SQ 29548 suppresses microglia/macrophage activation, inflammatory cytokine ( IL-1beta, IL-6, and TNF-alpha) production, iNOS release. SQ 29548 can be used for the research of ischemic stroke[2].